The efficacy of early use of recombinant soluble thrombomodulin for disseminated intravascular coagulation complicated with hematologic malignancies

DOI Web Site PubMed
  • USAMI Makoto
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • KURODA Hiroyuki
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • YOSHIDA Masahiro
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • SAKAMOTO Hiroki
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • SHIMOYAMA Saori
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • KANARI Yusuke
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • YAMADA Michiko
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • ABE Tomoyuki
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • FUJII Shigeyuki
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital
  • MAEDA Masahiro
    Department of Gastroenterology and Hematology/Clinical Oncology, Internal Medicine, Steel Memorial Muroran Hospital

Bibliographic Information

Other Title
  • 造血器悪性腫瘍に合併したDICに対する遺伝子組換え可溶型トロンボモジュリン早期使用の有用性
  • 臨床研究 第56回日本血液学会秋季北海道地方会 会長推薦演題 造血器悪性腫瘍に合併したDICに対する遺伝子組換え可溶型トロンボモジュリン早期使用の有用性
  • リンショウ ケンキュウ ダイ56カイ ニホン ケツエキ ガッカイ シュウキ ホッカイドウ チホウカイ カイチョウ スイセン エンダイ ゾウケツキ アクセイ シュヨウ ニ ガッペイ シタ DIC ニ タイスル イデンシ クミカエ カヨウガタ トロンボモジュリン ソウキ シヨウ ノ ユウヨウセイ

Search this article

Abstract

We retrospectively investigated treatment outcomes with soluble recombinant thrombomodulin (rTM) for disseminated intravascular coagulation (DIC) associated with hematological malignancies (acute leukemia and malignant lymphoma) at our hospital. After rTM administration, DIC scores improved in 29 of 39 cases with hematological malignancies (74.36%). Although one case with recurrent and refractory APL died due to cerebral bleeding during rTM administration, no bleeding-associated adverse events were observed in the other 38 cases. DIC improvement was augmented in cases with acute leukemia when rTM was introduced in the pre-DIC state. CRP decreased in 26 of 36 cases with hematological malignancies (72.22%) after rTM introduction, and CRP decreased particularly significantly in cases with malignant lymphoma, suggesting rTM to exert anti-inflammatory activity. Taken together, these observations indicate that rTM, which rarely causes bleeding-associated adverse events, is an excellent agent in terms of both efficacy and safety for treating DIC associated with hematological malignancies, and the potential anti-inflammatory activity of this agent was also suggested.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 56 (6), 673-680, 2015

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top